refine search
Authors
Locations
Journals
Publication Dates
Find concepts in Knowledge Base
Explore current query
documentsstatisticstop authorclipboard
30 documents found
1: Title: Sarcoidosis Related Novel Candidate Genes Identified by Multi-Omics Integrative Analyses.
Authors: Hočevar, Keli, et.al. .
Journal: Omics : a journal of integrative biology (Omics), 2018 .
Snippet: These new plausible candidate genes include NELFE, CFB, EGFL7, AGPAT2, FKBPL, NRC3, and NEU1.
Affiliation: 1 Clinical Institute of Medical Genetics, University Medical Centre Ljubljana , Ljubljana, Slovenia . 2 Biotechnical Faculty, Department of Animal Science, University of Ljubljana , Jamnikarjeva 101, Ljubljana, Slovenia . .
Related Products: order online
2: Title: Low-frequency nonsynonymous variants in FKBPL and ARPC1B genes are associated with breast cancer risk in Chinese women.
Authors: Zhou, Wen, et.al. .
Journal: Molecular carcinogenesis (Mol Carcinog), Vol. 56 (2): 774-780, 2017 .
Snippet: We identified two low-frequency nonsynonymous variants at FKBPL (rs200847762, OR = 0.34, 95% CI = 0.20-0.57,
Affiliation: State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, China. Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China. Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing, China. .
Related Products: order online
3: Title: Associations of 6p21.3 Region with Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy.
Authors: Ye, Zimeng, et.al. .
Journal: Scientific reports (Sci Rep), Vol. 6, 2016 .
Snippet: region, including CFB-SKIV2L-TNXB-FKBPL-NOTCH4 genes, with both neovascular AMD and PCV.
Affiliation: Sichuan Provincial Key Laboratory for Human Disease Gene Study, School of Medicine, Sichuan Academy of Medical Sciences &Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. College of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China. Health Management Center, Sichuan Provincial People's Hospital, Chengdu, China. Department of ophthalmology, Sichuan Provincial People's Hospital, Chengdu, China. Zhongshan Ophthalmic Center, Guangzhou, China. Clinical Medicine Department, Luzhou Medical College, Luzhou, China. Sichuan Translational Medicine Hospital, Chinese Academy of Sciences, Chengdu, China. .
Related Products: order online
4: Title: RALA-mediated delivery of FKBPL nucleic acid therapeutics.
Authors: Bennett, Rachel, et.al. .
Journal: Nanomedicine (London, England) (Nanomed), Vol. 10 (19): 2989-3001, 2015 .
Snippet: Here, we used RALA to deliver the FK506-binding protein like - FKBPL gene (pFKBPL) - a novel member of the immunophilin protein family.
Affiliation: School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland, UK. Northern Ireland Molecular Pathology Laboratory, Queen's University Belfast, Belfast, BT9 7BL, Northern Ireland, UK. .
Related Products: order online
5: Title: Novel endogenous angiogenesis inhibitors and their therapeutic potential.
Authors: Rao, Nithya, et.al. .
Journal: Acta pharmacologica Sinica (Acta Pharmacol Sin), Vol. 36 (10): 1177-90, 2015 .
Snippet: In this review, we highlight ten novel endogenous protein angiogenesis inhibitors discovered within the last five years, including ISM1, FKBPL, CHIP, ARHGAP18, MMRN2, SOCS3, TAp73, ZNF24, GPR56 and JWA.
Affiliation: Department of Biological Sciences, National University of Singapore, Singapore 117543, Singapore. .
Related Products: order online
6: Title: WISp39 and Hsp90: actin' together in cell migration.
Authors: Fotedar, Rati, et.al. .
Journal: Oncotarget, Vol. 6 (20): 17871-2, 2015 .
No Abstract available.
Affiliation: Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA, USA. .
Related Products: order online
7: Title: Low-frequency germline variants across 6p22.2-6p21.33 are associated with non-obstructive azoospermia in Han Chinese men.
Authors: Ni, Bixian, et.al. .
Journal: Human molecular genetics (Hum Mol Genet), Vol. 24 (19): 5628-36, 2015 .
Snippet: We identified three low-frequency variants located at 6p22.2 (rs2298090 in HIST1H1E encoding p.Lys152Arg: OR = 0.30, P = 2.40 × 10(-16)) and 6p21.33 (rs200847762 in FKBPL encoding p.Pro137Leu: OR = 0.11, P = 3.77 × 10(-16); rs11754464 in MSH5: OR = 1.78,
Affiliation: State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing 210029, China, Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center For Cancer Personalized Medicine, School of Public Health and. Institute of Dermatology and Department of Dermatology, No. 1 Hospital, Anhui Medical University, Hefei, Anhui 230022, China, Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, China, Hefei, Anhui 230022, China. Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center For Cancer Personalized Medicine, School of Public Health and. Shanghai Human Sperm Bank, Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China. State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing 210029, China, Department of Histology and Embryology, Nanjing Medical University, Nanjing 210029, China. State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing 210029, China, Department of Toxicology and Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing 211166, China. Family Planning Research Institute, Center of Reproductive Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430032, China. Jinghua Hospital, Shenyang Dongfang Medical Group, Shenyang 110004, China. Department of Reproduction, Shengjing Hospital, China Medical University, Shenyang 110004, China. Department of Andrology, Nanjing Jinling Hospital, Nanjing 210029, China. State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing 210029, China, Center of Clinical Reproductive Medicine, First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China. Department of Urology, Huashan Hospital, Shanghai 200052, China. Department of Genetics, Washington University School of Medicine, St Louis, MO 63110, USA, Department of Pathology & Immunology, Washington University School of Medicine, St Louis, MO 63110, USA. State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing 210029, China, Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center For Cancer Personalized Medicine, School of Public Health and State Key Laboratory of Genetic Engineering, Collaborative Innovation Center of Genetics and Development, Institute of Plant Biology, School of Life Sciences, Fudan University, Shanghai 200052, China, zhibin_hu@njmu.edu.cn shajh@njmu.edu.cn. State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing 210029, China, Department of Histology and Embryology, Nanjing Medical University, Nanjing 210029, China, zhibin_hu@njmu.edu.cn shajh@njmu.edu.cn. .
Related Products: order online
8: Title: Low-frequency coding variants at 6p21.33 and 20q11.21 are associated with lung cancer risk in Chinese populations.
Authors: Jin, Guangfu, et.al. .
Journal: American journal of human genetics (Am J Hum Genet), Vol. 96 (5): 832-40, 2015 .
Snippet: We identified three low-frequency missense variants in BAT2 (rs9469031, c.1544C>T [p.Pro515Leu]; odds ratio [OR] = 0.55, p = 1.28 × 10(-10)), FKBPL (rs200847762, c.410C>T [p.Pro137Leu]; OR = 0.25, p = 9.79 × 10(-12)), and BPIFB1 (rs6141383, c.850G>A [p.Val284Met]; OR = 1.72, p = 1.79 × 10(-7)); these variants were associated with lung cancer risk.
Affiliation: Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 211166, China; Jiangsu Key Laboratory of Cancer Biomarkers, Prevention, and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 211166, China. Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 211166, China. Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China. State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Department of Epidemiology, School of Public Health, China Medical University, Shenyang 110001, China. Medimmune, Gaithersburg, MD 20878, USA. Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA. Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, NH 03755, USA. Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 211166, China; Jiangsu Key Laboratory of Cancer Biomarkers, Prevention, and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 211166, China; Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China. Ministry of Education Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Bio-X Institutes, Shanghai Jiao Tong University, Shanghai 200240, China. Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 211166, China; Jiangsu Key Laboratory of Cancer Biomarkers, Prevention, and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 211166, China. Electronic address: hbshen@njmu.edu.cn. .
Related Products: order online
9: Title: FKBPL: a marker of good prognosis in breast cancer.
Authors: Nelson, Laura, et.al. .
Journal: Oncotarget, Vol. 6 (14): 12209-23, 2015 .
Snippet: For the sub-groups of 2365 estrogen receptor (ER) positive patients and 1649 tamoxifen treated patients, FKBPL was significantly associated with BCSS (HR = 1.34, 95% CI 1.13-1.58,
Affiliation: School of Pharmacy, Queen's University Belfast, Belfast, United Kingdom. Warwick Clinical Trials Unit, University of Warwick, Coventry, United Kingdom. Conway Institute, University College Dublin, Dublin, Ireland. Ontario Institute for Cancer Research, Toronto, Canada. Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, United Kingdom. Royal College of Surgeons Ireland, Dublin, Ireland. Northern Ireland Molecular Pathology Laboratory, CCRCB, Queens University Belfast, Belfast, United Kingdom. Department of Pathology, Royal Group of Hospitals, Grosvenor Road, Belfast, United Kingdom. Edinburgh Breast Unit, The University of Edinburgh, Edinburgh, United Kingdom. Department of Clinical Sciences, Lund University, Sweden. Edinburgh Cancer Research Centre, The University of Edinburgh, Edinburgh, United Kingdom. .
Related Products: order online
10: Title: WISp39 binds phosphorylated Coronin 1B to regulate Arp2/3 localization and Cofilin-dependent motility.
Authors: Howell, Michael, et.al. .
Journal: The Journal of cell biology (J Cell Biol), Vol. 208 (7): 961-74, 2015 .
Snippet: We conclude that WISp39 associates with Hsp90, Coronin 1B, and SSH to regulate Cofilin activation and Arp2/3 complex localization at the leading edge.
Affiliation: Sanford-Burnham Medical Research Institute, La Jolla, CA 92037. The Scripps Research Institute, La Jolla, CA 92037. Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA 92037. Sanford-Burnham Medical Research Institute, La Jolla, CA 92037 rfotedar@sanfordburnham.org. .
Related Products: order online
11: Title: FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis.
Authors: Yakkundi, Anita, et.al. .
Journal: Arteriosclerosis, thrombosis, and vascular biology (Arterioscler Thromb Vasc Biol), Vol. 35 (4): 845-54, 2015 .
Snippet: CONCLUSIONS: FKBPL is an important regulator of angiogenesis, having an essential role in murine and zebrafish blood vessel development.
Affiliation: From the McClay Research Centre for Pharmaceutical Sciences, School of Pharmacy (A.Y., R.B., M.H., O.L., A.S., H.M., L.N., C.M.M., R.M., L.M., H.O.M., T.R.), Centre for Infection and Immunity (M.H., O.L., A.K.), and Northern Ireland Molecular Pathology Laboratory, Centre for Cancer Research and Cell Biology (K.A.), School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, UK; School of Immunity and Infection and Cancer Studies, Institute for Biomedical Research, University of Birmingham, Birmingham, UK (I.H.-N., R.B.); Centre for Digestive Diseases, Queen Mary, University of London, Barts and The London School of Medicine and Dentistry, London, UK (J.-M.D.); and Birth Defects Research Centre, UCL Institute of Child Health, London, UK (J.-M.D., A.J.B.). From the McClay Research Centre for Pharmaceutical Sciences, School of Pharmacy (A.Y., R.B., M.H., O.L., A.S., H.M., L.N., C.M.M., R.M., L.M., H.O.M., T.R.), Centre for Infection and Immunity (M.H., O.L., A.K.), and Northern Ireland Molecular Pathology Laboratory, Centre for Cancer Research and Cell Biology (K.A.), School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, UK; School of Immunity and Infection and Cancer Studies, Institute for Biomedical Research, University of Birmingham, Birmingham, UK (I.H.-N., R.B.); Centre for Digestive Diseases, Queen Mary, University of London, Barts and The London School of Medicine and Dentistry, London, UK (J.-M.D.); and Birth Defects Research Centre, UCL Institute of Child Health, London, UK (J.-M.D., A.J.B.). t.robson@qub.ac.uk. .
Related Products: order online
12: Title: Biological relevance of Hsp90-binding immunophilins in cancer development and treatment.
Authors: Mazaira, Gisela I, et.al. .
Journal: International journal of cancer (Int J Cancer), Vol. 138 (4): 797-808, 2016 .
Snippet: They regulate the cytoplasmic transport and the subcellular localization of these and other Hsp90 client proteins, as well as transcriptional activity, cell proliferation, cell differentiation and apoptosis.
Affiliation: Departamento De Química Biológica, Facultad De Ciencias Exactas Y Naturales, Universidad De Buenos Aires and IQUIBICEN-CONICET, Buenos Aires, Argentina. Instituto De Biología Y Medicina Experimental-CONICET, Buenos Aires, Argentina. .
Related Products: order online
13: Title: Molecular cochaperones: tumor growth and cancer treatment.
Journal: Scientifica (Scientifica (cairo)), Vol. 2013, 2013 .
Snippet: Others such as the J domain protein family, HspBP1, TTC4, and FKBPL appear to be associated with more benign tumor phenotypes.
Affiliation: Division of Molecular and Cellular Biology, Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 99 Brookline Avenue, Boston, MA 02215, USA. .
Related Products: order online
14: Title: Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen.
Authors: Donley, C, et.al. .
Journal: Oncogene, Vol. 33 (26): 3441-50, 2014 .
Snippet: Both RBCK1 and FKBPL are upregulated by 17-β-estradiol and interact within heat shock protein 90 chaperone complexes, together with estrogen receptor-α (ERα).
Affiliation: School of Pharmacy, McClay Research Centre, Queen's University, Belfast, Northern Ireland. Liverpool Cancer Research UK Centre, University of Liverpool, Liverpool, UK. Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Northern Ireland. .
Related Products: order online
15: Title: Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
Authors: McClements, Lana, et.al. .
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res), Vol. 19 (14): 3881-93, 2013 .
Snippet: EXPERIMENTAL DESIGN: Mammosphere assays and flow cytometry were used to analyze the effect of FKBPL overexpression/knockdown and AD-01 treatment ± other anticancer agents on BCSCs using breast cancer cell lines (MCF-7/MDA-231/ZR-75), primary patient samples, and xenografts.
Affiliation: School of Pharmacy, Queen's University Belfast, Belfast, United Kingdom. .
Related Products: order online
16: Title: The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway.
Authors: Yakkundi, Anita, et.al. .
Journal: PloS one, Vol. 8 (2): e55075, 2013 .
Snippet: Inhibition of secreted FKBPL using a blocking antibody or siRNA-mediated knockdown of FKBPL accelerated the migration of human microvascular endothelial cells (HMEC-1).
Affiliation: School of Pharmacy, Queen's University Belfast, Northern Ireland, United Kingdom. .
Related Products: order online
17: Title: Genome-wide association study of age-related macular degeneration identifies associated variants in the TNXB-FKBPL-NOTCH4 region of chromosome 6p21.3.
Authors: Cipriani, Valentina, et.al. .
Journal: Human molecular genetics (Hum Mol Genet), Vol. 21 (18): 4138-50, 2012 .
Snippet: at TNXB (tenascin XB)-FKBPL (FK506 binding protein like) [rs12153855/rs9391734; discovery P =4.3 × 10(-7), replication P =3.0 × 10(-4), combined P =1.3 × 10(-9), odds ratio (OR) = 1.4,
Affiliation: Institute of Ophthalmology, University College London, London EC1V 9EL, UK. v.cipriani@ucl.ac.uk .
Related Products: order online
18: Title: The therapeutic and diagnostic potential of FKBPL; a novel anticancer protein.
Authors: Robson, Tracy, et.al. .
Journal: Drug discovery today (Drug Discov Today), Vol. 17 (11-12): 544-8, 2012 .
Snippet: A relatively new and divergent member of this family, FK506-binding protein like (FKBPL), is emerging as a key player in the DNA damage response, steroid receptor signalling and more recently, control of tumour growth where it regulates response to endocrine therapy in addition to acting as a novel antiangiogenic protein.
Affiliation: School of Pharmacy, Queen's University Belfast, UK. .
Related Products: order online
19: Title: The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL.
Authors: McKeen, Hayley D, et.al. .
Journal: Biochemical Society transactions (Biochem Soc Trans), Vol. 39 (2): 663-8, 2011 .
Snippet: FKBPL (FKBP-like) is a novel FKBP with roles in GR (glucocorticoid receptor), AR (androgen receptor) and ER (oestrogen receptor) signalling.
Affiliation: School of Pharmacy, McClay Research Centre, Queen's University, Belfast, UK. .
Related Products: order online
20: Title: FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.
Authors: Valentine, Andrea, et.al. .
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res), Vol. 17 (5): 1044-56, 2011 .
Snippet: RESULTS: rFKBPL inhibited endothelial cell migration, tubule formation, and microvessel formation in vitro and in vivo.
Affiliation: School of Pharmacy, Queen's University Belfast, Belfast, United Kingdom. .
Related Products: order online
Page 1 2 
Documents per page: 20 | 50 | 100